# Output Disclaimers & Safety Warnings

**Purpose:** Standardized disclaimers and safety warnings to prevent misuse of analysis results for clinical decision-making.

---

## Research Use Only Disclaimer

**Add to ALL analysis outputs (especially mcp-multiomics, PatientOne integration):**

```
âš ï¸  RESEARCH USE ONLY - NOT FOR CLINICAL DECISION-MAKING âš ï¸

This analysis is provided for RESEARCH PURPOSES ONLY and has not been
clinically validated. Results should NOT be used for:
  â€¢ Patient diagnosis
  â€¢ Treatment selection
  â€¢ Clinical decision-making
  â€¢ Publication without independent validation

All findings must be:
  1. Reviewed by qualified bioinformatics personnel
  2. Validated with orthogonal methods (e.g., qPCR, Western blot, IHC)
  3. Interpreted by board-certified oncologist before any clinical consideration

The developers assume NO liability for clinical decisions based on this output.
```

---

## Uncertainty Quantification

**For statistical results (p-values, fold changes, pathway predictions):**

### Confidence Level Indicators

Use these standard confidence levels in all statistical outputs:

```
ğŸ“Š Statistical Confidence:

â­â­â­ HIGH CONFIDENCE
  - p < 0.001 (after FDR correction)
  - Concordant across multiple modalities (RNA + Protein + Phospho)
  - Effect size log2FC > 2.0
  - Validated in independent datasets
  â†’ Findings likely robust, still require experimental validation

â­â­ MODERATE CONFIDENCE
  - p < 0.05 (after FDR correction)
  - Some modality disagreement
  - Effect size log2FC 1.0-2.0
  â†’ Findings plausible, require careful validation

â­ LOW CONFIDENCE
  - p < 0.1 (exploratory threshold)
  - Single modality only
  - Effect size log2FC < 1.0
  â†’ Exploratory finding only, hypothesis generation
```

### Always Report

For every statistical result, include:
- **p-values** (both raw and FDR-corrected)
- **Effect sizes** (log2FC, correlation coefficients, not just significance)
- **Sample size** and statistical power
- **Missing data percentage** per modality
- **Batch effects** detected and correction applied (if any)
- **Concordance** across modalities (for multi-omics)

### Example Usage

```python
result = {
    "gene": "PIK3CA",
    "meta_p_value": 0.0001,
    "meta_q_value": 0.002,  # FDR-corrected
    "log2FC": 2.3,
    "confidence": "HIGH",  # â­â­â­
    "evidence": {
        "rna_p": 0.001,
        "protein_p": 0.003,
        "phospho_p": 0.002,
        "concordance": "All modalities agree on upregulation"
    },
    "sample_size": 15,
    "missing_data_pct": 5,
    "recommendation": "High-confidence finding. Validate with qPCR and Western blot before clinical consideration."
}
```

---

## Data Quality Warnings

**When data quality is suboptimal, add explicit warnings:**

### Template: Data Quality Issues

```
âš ï¸  DATA QUALITY WARNING

The following data quality issues were detected:

Issue 1: Missing Values
  - RNA: 12% missing (imputed using KNN, k=5)
  - Protein: 18% missing (imputed using KNN, k=5)
  - Phospho: 25% missing (imputed using KNN, k=5)
  â†’ Impact: High missing rates may affect downstream analysis accuracy

Issue 2: Batch Effects
  - Detected: YES (PC1 correlates with batch, r=0.68, p<0.001)
  - Corrected: YES (using limma removeBatchEffect)
  - Residual correlation after correction: r=0.15, p=0.08
  â†’ Impact: Batch correction applied, but some residual effects remain

Issue 3: Low Sequencing Depth
  - Samples with <10M reads: 3/15 (20%)
  - Median depth: 12M reads (recommended: >20M)
  â†’ Impact: Low-depth samples may have reduced power to detect differential expression

Issue 4: Outlier Samples
  - Detected: 2 samples (Sample_07, Sample_12)
  - MAD > 3.0 from median
  - Action: Retained in analysis, flagged for review
  â†’ Impact: Outliers may skew results, consider sensitivity analysis

RECOMMENDATION:
Interpret results with caution due to data quality limitations.
Consider re-sequencing low-depth samples and validating top findings
with higher-quality data before publication.
```

### Template: Good Quality Data

```
âœ… DATA QUALITY: GOOD

Quality checks passed:
  â€¢ Missing values: <10% across all modalities
  â€¢ No significant batch effects detected (PC1 batch correlation r=0.08, p=0.52)
  â€¢ Sequencing depth: All samples >15M reads
  â€¢ No outlier samples detected (all within MAD < 2.5)

Data is suitable for downstream analysis with standard interpretation.
```

---

## Upstream Regulator Predictions

**For kinase/TF/drug target predictions (mcp-multiomics tool):**

```
âš ï¸  UPSTREAM REGULATOR PREDICTIONS - COMPUTATIONAL INFERENCE âš ï¸

These predictions are based on:
  â€¢ Database annotations (PhosphoSitePlus, TRRUST, TRANSFAC)
  â€¢ Enrichment analysis (Fisher's exact test)
  â€¢ Activation state inference (Z-score method)

Limitations:
  â€¢ Predictions are COMPUTATIONAL, not experimental
  â€¢ Database annotations may be incomplete or context-specific
  â€¢ Activation states are inferred, not directly measured
  â€¢ Drug targets are predicted based on pathway activation, not drug efficacy

Required Validation:
  1. Kinase predictions: Validate with kinase assays or phospho-specific antibodies
  2. TF predictions: Validate with ChIP-seq or reporter assays
  3. Drug predictions: Validate in appropriate cell/animal models
  4. Clinical use: Requires clinical trial evidence

Do NOT use these predictions for:
  â€¢ Direct patient treatment decisions
  â€¢ Drug selection without clinical evidence
  â€¢ Publication without experimental validation
```

---

## Pathway Enrichment Results

**For pathway analysis outputs:**

```
âš ï¸  PATHWAY ENRICHMENT - HYPOTHESIS GENERATION TOOL âš ï¸

Pathway enrichment identifies biological processes potentially affected
by your gene/protein changes. These are HYPOTHESES, not proven mechanisms.

Interpretation Guidelines:
  â€¢ q-value < 0.05: Statistically enriched pathway
  â€¢ q-value < 0.01: Strongly enriched pathway
  â€¢ Overlap: Higher gene overlap = stronger evidence

Limitations:
  â€¢ Based on annotation databases (may be incomplete)
  â€¢ Does not prove causal mechanism
  â€¢ Context-dependent (cell type, species, condition)
  â€¢ Biased toward well-studied pathways

Follow-up Validation:
  1. Review individual genes in pathway
  2. Check literature for pathway relevance to your biological question
  3. Validate key pathway components with targeted experiments
  4. Consider pathway crosstalk and indirect effects
```

---

## Multi-Omics Integration

**For integrated RNA/Protein/Phospho analysis:**

```
â„¹ï¸  MULTI-OMICS INTEGRATION NOTES

This analysis integrates RNA, protein, and phosphorylation data using
Stouffer's meta-analysis. Understanding the relationships:

RNA â†’ Protein â†’ Phosphorylation

Expected Concordance:
  â€¢ RNAâ†‘ + Proteinâ†‘ = High confidence (transcriptional regulation)
  â€¢ RNAâ†” + Proteinâ†‘ = Moderate confidence (post-transcriptional regulation)
  â€¢ RNAâ†‘ + Proteinâ†” + Phosphoâ†‘ = High confidence (post-translational activation)

Discordance May Indicate:
  â€¢ Post-transcriptional regulation (miRNA, RNA binding proteins)
  â€¢ Post-translational modifications (ubiquitination, acetylation)
  â€¢ Protein stability changes
  â€¢ Technical artifacts or batch effects

Interpretation:
  â€¢ Concordant signals (all modalities agree) = HIGH confidence
  â€¢ Mixed signals = Requires mechanistic investigation
  â€¢ Discordant signals = May indicate complex regulation OR technical issues
```

---

## Spatial Transcriptomics

**For spatial analysis results:**

```
âš ï¸  SPATIAL TRANSCRIPTOMICS - RESOLUTION LIMITATIONS âš ï¸

10x Visium spatial transcriptomics provides tissue-level resolution,
not single-cell resolution.

Technical Specifications:
  â€¢ Spot diameter: 55 Î¼m
  â€¢ Center-to-center distance: 100 Î¼m
  â€¢ Cells per spot: 1-10 (typically 3-5)
  â€¢ Genes detected: ~5,000-10,000 per spot

Limitations:
  â€¢ Cannot resolve individual cells within spots
  â€¢ Gene expression is AVERAGE across cells in each spot
  â€¢ Cell type deconvolution is computational inference
  â€¢ Spatial resolution lower than microscopy

Appropriate Uses:
  âœ… Tissue region identification
  âœ… Regional gene expression patterns
  âœ… Tumor microenvironment architecture
  âœ… Immune infiltration patterns

Inappropriate Uses:
  âŒ Single-cell resolution claims
  âŒ Precise cell-cell interaction mapping
  âŒ Exact cell type proportions (use as estimates only)
```

---

## Treatment Recommendations

**For any therapeutic suggestions:**

```
ğŸ”´ CRITICAL: TREATMENT RECOMMENDATIONS - EXPERIMENTAL ONLY ğŸ”´

ANY treatment recommendations in this analysis are:
  â€¢ Based on COMPUTATIONAL predictions from genomic/transcriptomic data
  â€¢ NOT based on clinical trial evidence
  â€¢ NOT FDA-approved for this indication
  â€¢ NOT a substitute for clinical judgment

Required Before Clinical Consideration:
  1. âœ… Review by board-certified oncologist
  2. âœ… Tumor board discussion
  3. âœ… Published clinical evidence for indication
  4. âœ… FDA approval or clinical trial availability
  5. âœ… Patient eligibility assessment
  6. âœ… Risk/benefit analysis

Examples of Appropriate Use:
  âœ… Identifying potential drug targets for research
  âœ… Prioritizing genes for functional studies
  âœ… Generating hypotheses for clinical trial design
  âœ… Identifying resistance mechanisms for investigation

Examples of INAPPROPRIATE Use:
  âŒ Prescribing drugs directly based on predictions
  âŒ Making treatment decisions without clinical evidence
  âŒ Bypassing standard-of-care therapies
  âŒ Clinical use without IRB approval

REMEMBER: Computational predictions â‰  Clinical recommendations
```

---

## PatientOne Workflow Disclaimer

**For comprehensive PatientOne analysis outputs:**

```
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘                     PATIENTONE WORKFLOW DISCLAIMER                         â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

This PatientOne analysis integrates:
  â€¢ Clinical data (demographics, treatment history)
  â€¢ Genomic variants (somatic mutations, CNVs)
  â€¢ Multi-omics data (RNA, Protein, Phosphorylation)
  â€¢ Spatial transcriptomics (tumor microenvironment)
  â€¢ Histology imaging (H&E, multiplex IF)

âš ï¸  CRITICAL LIMITATIONS:

1. RESEARCH USE ONLY
   This workflow has NOT been clinically validated.
   Do NOT use for patient care decisions.

2. SYNTHETIC/DE-IDENTIFIED DATA
   If using real patient data, ensure:
   âœ… IRB approval obtained
   âœ… Data de-identified per HIPAA guidelines
   âœ… Informed consent for research use

3. AI-GENERATED INSIGHTS
   Claude AI orchestrates the analysis but:
   â€¢ May misinterpret complex data
   â€¢ May hallucinate connections not supported by data
   â€¢ Cannot replace expert human interpretation
   â€¢ Requires validation by qualified bioinformaticians

4. VALIDATION REQUIRED
   ALL findings must be validated:
   â€¢ Statistical findings â†’ Independent cohort
   â€¢ Pathway predictions â†’ Mechanistic studies
   â€¢ Drug targets â†’ Experimental models
   â€¢ Clinical recommendations â†’ Clinical trials

5. NO LIABILITY
   The developers and AI provider assume NO liability for:
   â€¢ Treatment decisions based on this analysis
   â€¢ Patient outcomes
   â€¢ Misinterpretation of results
   â€¢ Technical errors or bugs

â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘  CONSULT A QUALIFIED ONCOLOGIST BEFORE ANY CLINICAL DECISION               â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## Example: Complete Analysis Output with Disclaimers

```python
def generate_multiomics_report():
    """Example of properly disclaimed analysis output."""

    report = """
âš ï¸  RESEARCH USE ONLY - NOT FOR CLINICAL DECISION-MAKING âš ï¸

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
MULTI-OMICS TREATMENT RESISTANCE ANALYSIS
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

Patient: PAT001-OVC-2025 (DE-IDENTIFIED)
Analysis Date: 2025-12-27
Modalities: RNA-seq, Proteomics, Phosphoproteomics (15 PDX samples)

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
KEY FINDINGS
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

1. PI3K/AKT/mTOR Pathway Activation â­â­â­ HIGH CONFIDENCE
   - PIK3CA: log2FC=2.3, q=0.0001 (RNA+Protein concordant)
   - AKT1 phospho(S473): log2FC=1.8, q=0.002
   - mTOR: log2FC=1.5, q=0.01

   Validation Required:
   â†’ Western blot for p-AKT(S473), p-mTOR(S2448)
   â†’ PI3K kinase activity assay

2. TP53 Loss of Function â­â­â­ HIGH CONFIDENCE
   - Mutation: TP53 c.524G>A (p.R175H) - known hotspot
   - RNA: log2FC=-2.1, q<0.0001
   - Protein: log2FC=-1.8, q=0.001

   Clinical Context:
   â†’ TP53 mutations present in >96% of HGSOC
   â†’ Validates expected HGSOC molecular profile

3. Immune Exclusion Phenotype â­â­ MODERATE CONFIDENCE
   - CD8A: log2FC=-1.2, q=0.02
   - CD8B: log2FC=-1.1, q=0.03
   - Based on spatial transcriptomics (tumor core vs invasive margin)

   Limitations:
   â†’ Spatial resolution: 55Î¼m spots (3-5 cells per spot)
   â†’ Requires validation with IHC for CD8+ T cells

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
PREDICTED THERAPEUTIC TARGETS (COMPUTATIONAL INFERENCE)
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

âš ï¸  These are COMPUTATIONAL PREDICTIONS, not clinical recommendations

1. PIK3CA Inhibitors (e.g., Alpelisib)
   Rationale: PIK3CA upregulation and pathway activation
   Evidence Level: â­â­ MODERATE
   Clinical Status: FDA-approved for HR+ breast cancer, not ovarian

   âš ï¸  OFF-LABEL for ovarian cancer
   âš ï¸  Requires tumor board review and clinical trial availability

2. mTOR Inhibitors (e.g., Everolimus)
   Rationale: mTOR pathway activation
   Evidence Level: â­â­ MODERATE
   Clinical Status: FDA-approved for other indications

   âš ï¸  Limited clinical evidence in platinum-resistant ovarian cancer
   âš ï¸  Consider in context of clinical trial

3. Immune Checkpoint Inhibitors (e.g., Pembrolizumab + combinations)
   Rationale: Immune exclusion suggests need for immune activation
   Evidence Level: â­ LOW (exploratory)

   âš ï¸  HGSOC generally has low response to ICI monotherapy
   âš ï¸  Consider combination strategies in clinical trial setting

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
DATA QUALITY ASSESSMENT
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

âœ… GOOD DATA QUALITY

  â€¢ Missing values: RNA 8%, Protein 15%, Phospho 22%
  â€¢ Batch effects: Corrected (PC1 batch correlation: 0.68 â†’ 0.12)
  â€¢ Sample size: 15 (7 resistant, 8 sensitive) - adequate power
  â€¢ Outliers: None detected (all within MAD < 2.5)

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
REQUIRED VALIDATION STEPS
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

Before clinical consideration:

1. âœ… Orthogonal Validation
   - Western blot: p-AKT(S473), p-mTOR(S2448), TP53
   - IHC: CD8+ T cell infiltration
   - qPCR: PIK3CA, AKT1, mTOR expression

2. âœ… Functional Studies
   - PI3K inhibitor sensitivity assays in patient-derived cells
   - Combination therapy testing (PI3K + immune checkpoint)

3. âœ… Clinical Review
   - Tumor board presentation
   - Review of standard-of-care options
   - Clinical trial matching
   - Patient eligibility and preferences

4. âœ… Regulatory Compliance
   - IRB approval for off-label use (if applicable)
   - Informed consent
   - Insurance pre-authorization

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

âš ï¸  FINAL REMINDER:

This analysis is for RESEARCH PURPOSES ONLY.
All findings require experimental validation and clinical review.
Do NOT use for patient treatment decisions without proper validation.

Consult a board-certified oncologist before any clinical consideration.

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

Analysis generated by: Precision Medicine MCP (mcp-multiomics v2.0)
Disclaimer version: 1.0 (2025-12-27)

"""
    return report
```

---

## Quick Reference: When to Use Each Disclaimer

| Output Type | Required Disclaimers |
|-------------|---------------------|
| **Statistical Results** | Research Use Only + Confidence Levels + Data Quality |
| **Pathway Enrichment** | Research Use Only + Pathway Disclaimer |
| **Upstream Regulators** | Research Use Only + Upstream Regulator Disclaimer |
| **Drug Predictions** | Research Use Only + Treatment Recommendations (CRITICAL) |
| **Spatial Analysis** | Research Use Only + Spatial Transcriptomics Limitations |
| **Multi-Omics Integration** | Research Use Only + Multi-Omics Notes + Data Quality |
| **PatientOne Complete** | PatientOne Workflow Disclaimer (comprehensive) |
| **Any Clinical Context** | Treatment Recommendations (CRITICAL) |

---

## Implementation Checklist

- [ ] Add `docs/DISCLAIMERS.md` to repository
- [ ] Update mcp-multiomics tools to include appropriate disclaimers
- [ ] Add PatientOne disclaimer to README and test documentation
- [ ] Include confidence levels in all statistical outputs
- [ ] Add data quality reporting to preprocessing tools
- [ ] Train users on disclaimer interpretation
- [ ] Review disclaimers with legal counsel (if deploying in clinical setting)

---

**Last Updated:** December 27, 2025
**Maintained by:** Precision Medicine MCP Team
**Review Schedule:** Update before any production deployment or change in use case
